Clinical Research, Pharma & Healthcare FinancingInnate Pharma Doses First Patient in Phase 1 Study of IPH4502Business WireJanuary 27, 2025February 21, 2025 by Business WireJanuary 27, 2025February 21, 2025027 IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4 Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)...
